MiniMed Group (MMED) is up 3.7% today. Here is some analysis on what might have caused this price movement.
Analysis: The most likely driver is FDA clearance for MiniMed Fit, the company’s first tubeless insulin pump, which opens a new product category for MiniMed and brings its U.S. launch forward to spring 2027. Investors appear to be focusing on the earlier commercialization opportunity and the added growth potential, even though the clearance also triggered a sizable one-time accounting charge tied to a prior financing arrangement.
Details:
Sources:
MiniMed, SEC
Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.
$MMED Hedge Fund Activity
We have seen 102 institutional investors add shares of $MMED stock to their portfolio, and 39 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 2,326,082 shares (+215.2%) to their portfolio in Q3 2026, for an estimated $45,288,816
- UBS GROUP AG added 2,323,234 shares (+562.0%) to their portfolio in Q3 2026, for an estimated $45,233,365
- ALYESKA INVESTMENT GROUP, L.P. removed 2,000,000 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $29,900,000
- NORGES BANK added 1,961,002 shares (+inf%) to their portfolio in Q2 2026, for an estimated $29,316,979
- HOOD RIVER CAPITAL MANAGEMENT LLC removed 1,505,778 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $22,511,381
- EXODUSPOINT CAPITAL MANAGEMENT, LP added 1,437,067 shares (+inf%) to their portfolio in Q2 2026, for an estimated $21,484,151
- WALLEYE CAPITAL LLC added 1,399,301 shares (+inf%) to their portfolio in Q3 2026, for an estimated $27,244,390
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$MMED Analyst Ratings
Wall Street analysts have issued reports on $MMED in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 10/08/2026
- Truist Securities issued a "Buy" rating on 09/24/2026
- Morgan Stanley issued a "Overweight" rating on 09/03/2026
- Citigroup issued a "Buy" rating on 09/02/2026
- Evercore ISI Group issued a "Outperform" rating on 09/02/2026
- Wells Fargo issued a "Overweight" rating on 09/02/2026
- UBS issued a "Buy" rating on 09/02/2026
To track analyst ratings and price targets for $MMED, check out Quiver Quantitative's $MMED forecast page.
$MMED Price Targets
Multiple analysts have issued price targets for $MMED recently. We have seen 12 analysts offer price targets for $MMED in the last 6 months, with a median target of $26.5.
Here are some recent targets:
- Christopher Pasquale from Barclays set a target price of $20.0 on 11/13/2026
- Michael Toomey from Jefferies set a target price of $22.0 on 10/12/2026
- Anthony Petrone from Mizuho set a target price of $28.0 on 10/08/2026
- Richard Newitter from Truist Securities set a target price of $29.0 on 09/24/2026
- Kallum Titchmarsh from Morgan Stanley set a target price of $21.0 on 09/03/2026
- Joanne Wuensch from Citigroup set a target price of $26.0 on 09/02/2026
- Daniel Markowitz from Evercore ISI Group set a target price of $27.0 on 09/02/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.